John L. Marshall, MD, on Accessibility of Precision Medicine

Video

The expert from the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers discussed precision medicine with regard to cancer care, as well as the need to make such care more accessible for the global community.

In an article published in the journal Oncology®, John L. Marshall, MD, of the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discussed precision medicine with regard to cancer care, as well as the need to make such care more accessible for the global community.

“Cancer care can no longer be a luxury item, only for the rich. We must work toward wide access,” Marshall wrote. “Opening markets through collaborative science will secure the return on investment for our business partners, and secure our progress toward finding the cures for cancer.”

In an interview with CancerNetwork®, Marshall spoke about his paper further and why precision medicine will change global cancer care for decades to come.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

Marshall JL. The Prospective Incorporation of Molecular Profiling Will Transform Global Cancer Care. Oncology. https://www.cancernetwork.com/view/the-prospective-incorporation-of-molecular-profiling-will-transform-global-cancer-care

Recent Videos
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.